Philip Russmeyer: Revolutionising clinical trials with true data anonymization

Send us Fan MailThis week we speak to Philip Russmeyer, Founder & CEO of Fitfile, about the promises that true data anonymization holds for transforming clinical trials. We dive into the differences between tokenization, anonymization and pseudonymisation of data. And how the difference is whether individuals can ever be identified or if the data is masked with a token that can potentially be removed. The risk of secondary use of data that has been tokenized has held back research and data sharing between healthcare and life sciences. One of the reasons is that collecting consent from individuals costs about 400 USD per consent.One of the downsides of anonymization is that data cannot be unified across sources for an individual to get a full picture of health data. We speak about the differences between US and EU attitudes and legislation about personal data protection and how these are converging towards stronger privacy protection. For good reason, since personal health data is worth 10x more on the dark web compared to financial data. Collection of consent also matters in the sense that 80-90% of a trial is still delayed due to longer recruitment timelines than anticipated. That can be reduced if the trial protocol rests on a larger volume of anonymized relevant data.Anonymized data can also serve as a larger and more ethical control arm for clinical trials. Same goes for long-term follow up of clinical trials and the potential to re-use data collected once in additional trials.   We speak about the siloed nature of health data between healthcare and life sciences and how Fitfile attempts to work end-to-end between the entire data creation lifecycle. Which is not always simple, but optimises the use of health data.  Guest:https://www.linkedin.com/in/philiprussmeyer/ Fitfilehttps://www.linkedin.com/company/fitfile/ Notes: GPDPR Program of the NHS: https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-collections/general-practice-data-for-planning-and-research European Journal of Human Genetics: https://www.nature.com/ejhg/ ADPPA:Visit Labtolives.com Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/ Would you like to join the show as a guest or collaborator? Find out how on our website: https://www.labtolives.com/ Support the show________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn pageVisit www.labtolives.com HostsAlexander Booth aka the MedTech GuyDimitri Borisevich aka the start-up GuyIvanna Rosendal aka the R&D pharma Gal